A study presented at the 2020 ASCO meeting found that IV hydromorphone administered via patient-controlled analgesia provided quicker pain relief and higher patient satisfaction for those with severe cancer pain compared to other pain control methods. This randomized phase 3 study involved 214 patients at 17 sites in China, with a numerical rating scale score indicating severe pain. The results showed that hydromorphone was well-tolerated and effective in managing cancer pain, suggesting it may be a preferred option for this patient population.
Source link